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Early accumulation of intracellular fibrillar oligomers
and late congophilic amyloid angiopathy in mice
expressing the Osaka intra-Ab APP mutation
L Kulic1,2,3, J McAfoose1, T Welt1, C Tackenberg1, C Spa¨ni1, F Wirth1, V Finder1, U Konietzko1, M Giese4, A Eckert4, K Noriaki5,
T Shimizu6, K Murakami7, K Irie7, S Rasool8, C Glabe8, C Hock1 and RM Nitsch1
Pathogenic amyloid-b peptide precursor (APP) mutations clustered around position 693 of APP—position 22 of the Ab
sequence—are commonly associated with congophilic amyloid angiopathy (CAA) and intracerebral hemorrhages. In contrast,
the Osaka (E693D) intra-Ab APP mutation shows a recessive pattern of inheritance that leads to AD-like dementia despite low
brain amyloid on in vivo positron emission tomography imaging. Here, we investigated the effects of the Osaka APP mutation on
Ab accumulation and deposition in vivo using a newly generated APP transgenic mouse model (E22DAb) expressing the Osaka
mutation together with the Swedish (K670N/M671L) double mutation. E22DAb mice exhibited reduced a-processing of APP and
early accumulation of intraneuronal fibrillar Ab oligomers associated with cognitive deficits. In line with our in vitro findings that
recombinant E22D-mutated Ab peptides form amyloid fibrils, aged E22DAb mice showed extracellular CAA deposits in
leptomeningeal cerebellar and cortical vessels. In vitro results from thioflavin T aggregation assays with recombinant Ab
peptides revealed a yet unknown antiamyloidogenic property of the E693D mutation in the heterozygous state and an inhibitory
effect of E22D Ab42 on E22D Ab40 fibrillogenesis. Moreover, E22D Ab42 showed a unique aggregation kinetics lacking
exponential fibril growth and poor seeding effects on wild-type Ab aggregation. These results provide a possible explanation for
the recessive trait of inheritance of the Osaka APP mutation and the apparent lack of amyloid deposition in E693D mutation
carriers.
Translational Psychiatry (2012) 2, e183; doi:10.1038/tp.2012.109; published online 13 November 2012
Introduction
Extracellular deposition of fibrillar amyloid-b (Ab) peptide as
amyloid plaques and congophilic amyloid angiopathy (CAA) is
considered a cardinal neuropathological feature of Alzhei-
mer’s disease (AD).1,2 According to the amyloid cascade
hypothesis, soluble and fibrillar Ab species have a central role
in the pathogenesis of AD and start to accumulate within the
brain years before cognitive decline and dementia symptoms
are observed.3 Evidence supporting the amyloid cascade
hypothesis comes from several sources including genetic
studies of familial AD cases carrying mutations in the amyloid-
b peptide precursor (APP) gene and the presenilin genes.3,4
Pathogenic mutations in the APP gene have been shown to
influence the metabolism of the Ab peptide in various ways.
The Swedish double mutation (K670N/M671L), located
upstream of the Ab N terminus adjacent to the b-cleavage
site, results in an increased production of both Ab40 and Ab42
species,5–7 whereas mutations located at the g-cleavage site
of APP cause an increase of the Ab42/Ab40 ratio and, as a
consequence of this, result in increased Ab aggregation and
deposition (for a review see Goate8). The recently discovered
E693D Osaka mutation in a Japanese pedigree9 is one of the
six so-called intra-Ab mutations clustered around the hydro-
phobic core of the Ab sequence. Position 693 seems to be a
critical site involved in pathogenic aggregate formation since
mutations at or (±1) around this site, including the Dutch
(E693Q),10 Flemish (E692G),11 Italian (E693K),12 Iowa
(D694N)13 and Arctic (E693G)14 mutations, have been
reported to result in an increase in total Ab production15
and—with the exception of the Flemish mutation—enhance
Ab aggregation and toxicity.16,17 Interestingly, all currently
known intra-Ab APP mutations—with the exception of
E693D—have previously been shown to be vasculotropic
and are characterized neuropathologically by prominent
vascular amyloid deposition.18
Although neuropathological data have not been reported to
date, homozygous carriers of the recessive Osaka APP
mutation are believed to develop an AD-like clinical phenotype
in the absence of relevant extracellular amyloid deposition as
revealed by a very low signal on amyloid positron emission
tomography imaging.9 In vitro experiments demonstrated
enhanced oligomerization but no fibrillization of synthetic
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E22DAb40 and E22DAb42 preparations, suggesting that AD-
like symptoms may be caused by the presence of synapto-
toxic Ab oligomers, rather than fibrillar Ab, in the affected
patients.9 Consistent with these findings, synthetic E22D
Ab42 potently inhibited hippocampal long-term potentia-
tion9,19 and induced synapse loss in mouse hippocampal
slices.20 Further cell culture experiments and results from the
recently reported E693D transgenic mouse model revealed
enhanced accumulation of intraneuronal Ab oligomers as a
prominent feature of the Osaka APP mutation.21–23 E693D
transgenic mice start to accumulate intraneuronal Ab aggre-
gates at an age of 8 months and are completely devoid of
extracellular amyloid deposits up to an age of 24 months.22
The apparent lack of extracellular amyloid deposition in these
mice has been suggested to be in line with the initial in vitro
findings with synthetic Ab preparations that E22D-mutated Ab
peptides do not form amyloid fibrils.9
However, follow-up studies with recombinant Ab prepara-
tions revealed that both E22D Ab40 and E22D Ab42 readily
formed amyloid fibrils in vitro.24 Based on these findings, we
hypothesized that E22D-mutated Ab may, in principle, also
form amyloid fibrils in vivo and generated a novel APP
transgenic mouse line (E22DAb) to investigate the effects of
the E693D mutation on amyloid accumulation and deposition
in vivo. In line with our recent in vitro findings,24 aged E22DAb
mice were characterized by late extracellular amyloid deposi-
tion in the leptomeningeal vasculature at 24 months of age,
which was preceded by an early accumulation of intracellular
oligomeric Ab species already at an age of 3 months. The
results of this study provide strong evidence that E22D-
mutated Ab species are fibrillogenic and can deposit extra-
cellularly in vivo as CAA, thus placing the E693D Osaka
mutation on the list of other vasculotropic intra-Ab APP
mutations.
Materials and methods
Animals. The newly generated E22DAb mice express the
human APP695 isoform containing the Swedish (K670Nþ
M671L) and Osaka (E693D) mutations. The mutations were
generated by site-directed mutagenesis of pGEM-9zf( )-
huAPP695. The cDNA was inserted into pMoPrP-Xho,25 and
the construct was sequenced. After removal of the vector
sequence, the linear construct was injected into the pronuclei
of fertilized zygotes of B6D2F1 mice. Founders were
screened for transgene expression by tail polymerase chain
reaction and western blot analysis, and the line used in this
project was expanded on the hybrid background of C57Bl/6
and DBA/2 (B6D2). For all behavioral, biochemical and
histological analyses, offspring from the B6D2 generation
backcrossed once with pure C57Bl/6 was used. Mice were
kept on a 12 h light/dark cycle at 22 1C. Food pellets and
water were available ad libitum.
For histological and western blot analyses, mice at different
ages were anesthetized and transcardially perfused with ice-
cold phosphate-buffered saline. One hemibrain was dissected
into cortex and hippocampus, frozen in liquid nitrogen and
stored at –80 1C. The other hemibrain was postfixed in 4%
(w v 1) paraformaldehyde in phosphate-buffered saline over-
night at 4 1C and embedded in paraffin.
All animal experiments were performed in compliance with
Swiss national guidelines and were approved by the
veterinarian authorities of the Canton of Zurich.
Protein extracts and western blotting. Brain tissues were
homogenized with a glass teflon homogenizer in a sixfold wet
weight amount of buffer A containing 100mM Tris-HCl,
150mM NaCl, Complete Protease Inhibitor Cocktail (Roche
Diagnostics, Rotkreuz, Switzerland) and Phosphatase Inhi-
bitor Cocktails 1þ 2 (Sigma-Aldrich, Buchs, Switzerland).
After centrifugation at 100 000g for 1 h, supernatants were
collected (¼Tris fraction) and pellets were rehomogenized
in buffer A containing 1% Triton X-100. Centrifugation at
100 000g was repeated and supernatants were again collec-
ted (¼Triton fraction). The remaining pellets were rehomo-
genized in buffer A containing 2% sodium dodecyl sulfate
(SDS). After an additional centrifugation step and collection
of the supernatants (¼SDS fraction), the resulting pellets
were eventually dissolved in 70% formic acid (FA), sonicated
for 30 s at 30% power, ultracentrifuged, supernatants
extracted, lyophilized and reconstituted in buffer A containing
2% SDS for further analysis. Total protein concentrations
were measured with the DC protein assay (Bio-Rad Labs,
Gessier, Switzerland). Extracts were separated by SDS-
polyacrylamide gel electrophoresis, blotted onto nitrocellu-
lose, boiled for 5min in phosphate-buffered saline and
blocked in Tris-buffered saline containing 5% milk for 1 h at
room temperature. Primary antibodies were incubated over-
night at 4 1C (6E10 1:500; anti-C-terminal APP (Sigma,
Buchs, Switzerland); 1:2000) and visualized by peroxidase-
conjugated antibodies and ECL reactions (Amersham Bio-
sciences, Otelfingen, Switzerland). Monoclonal anti-b-actin
antibody (1:2000; Abcam, Cambridge, UK) was used as
internal loading control and for normalization of densitometric
analyses of the immunoreactive bands. Quantification of the
immunoreactive bands was carried out by densitometry of
the scanned films under conditions of non-saturated signal
using the Image J software (rsb.info.nih.gov/ij/).
MSD analysis. Ab fragments were measured in the above-
mentioned brain homogenate fractions and plasma was
measured using a MesoScale Discovery (MSD) 3plex multi-
SPOT Ab human kit (Gaithersburg, MD, USA) for Ab38, Ab40
and Ab42, in accordance with the manufacturer’s instructions.
Human sAPPa levels were determined using an MSD 2plex
kit (Gaithersburg, MD, USA), and human Swedish sAPPb
levels were determined using an MSD 1plex kit (Gaithersburg,
MD, USA), in accordance with the manufacturer’s instruc-
tions. All reagents were provided with the kits containing a
96-well plate with two carbon electrodes precoated with
analyte-specific capture antibodies. After 1 h of blocking with
bovine serum albumin, plates were washed with Tris wash
buffer and samples and standards added to the wells. Plates
were sealed and incubated for 1 h on an orbital shaker
(750 r.p.m.) at room temperature, followed by additional
washing steps and incubation with the detection antibody for
1 h. For Ab 3plex assay (Gaithersburg, MD, USA), standards
and samples were added at the same time as the detection
antibody, and plates were incubated for 2 h. At the end of the
incubation period, plates were washed again and measured
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on an MSD SECTOR Imager 6000 plate reader (Gaithersburg,
MD, USA) after the addition of the MSD Read Buffer T
(Gaithersburg, MD, USA). Raw data were measured as
electrochemiluminescence (light) signal detected by photo-
detectors. The MSD DISCOVERY WORKBENCH software
(Version 3.0.17) (Gaithersburg, MD, USA) with Data Analysis
Toolbox was used to calculate sample concentrations by
comparing them against a standard curve.
Histological analysis. Histological stainings were carried
out on 5 mm paraffin brain sections by using standard
published procedures. For the immunohistochemical detec-
tion of intraneuronal Ab deposits, sections were boiled in
10mM sodium citrate buffer (pH 6.0), followed by antigen
retrieval with 95% FA for 5min. The following antibodies
were used for immunohistochemistry: 6E10 (1:500 dilution;
Signet, Dedham, MA, USA) and b-amyloid antibody (1:200
dilution; Cell Signaling, Danvers, MA, USA) were used for the
detection of pan-Ab. Anti-b-amyloid protein (1–40) antibody
(1:100; Sigma) and BA27 (Amyloid b-Protein Immunohistos-
tain Kit; Wako, Wako Chemicals GmbH, Neuss, Germany)
were used to specifically detect Ab40. b-Amyloid 42
Polyclonal Antibody (1:100; Signet) and BC05 (Amyloid
b-Protein Immunohistostain Kit; Wako) were used to speci-
fically detect Ab42. Polyclonal antibodies A11 and OC
(provided by C Glabe, both 1:100) were used for the
detection of prefibrillar and fibrillar Ab oligomers, respec-
tively. 11A1 (1:100; IBL Japan, Gunma, Japan) was used to
detect Ab with a conformational turn epitope between
positions 22 and 23 of the Ab sequence.26 Anti-Amyloid
Precursor Protein, C-Terminal antibody (1:200; Sigma) was
used for the detection of full-length APP and APP C-terminal
fragments. Secondary antibodies were obtained from Vector
Laboratories, Burlingame, CA, USA (Vectastain ABC kits
PK-6101 and PK-6102) for peroxidase diaminobenzidine
stainings, and from Jackson Immunoresearch Laboratories
(West Grove, PA, USA) for immunofluorescence.
Thioflavin S staining and Congo red stainings were
performed according to standard protocols as described
previously.27
Recombinant Ab production. Production of recombinant
Ab peptides (wild-type Ab40 and Ab42, E22D Ab40 and
Ab42, and E22G Ab40 and Ab42) was performed as
described previously.28 In brief, recombinant Ab peptides
were expressed under the control of the T7 promoter/lac
operator in Escherichia coli BL21 (DE3) as fusion proteins to
the peptide sequence (NANP)19 with an N-terminal hexahis-
tidine tag. Mutagenesis at codon 22 in both Ab1–40 and
Ab1–42 was performed with the QuikChange site-directed
mutagenesis kit (Stratagene, Basel, Switzerland). The
correct genetic sequences of the constructs were verified
by DNA sequencing. Cleavage of the fusion proteins (100 mM)
with 7.5 mM tobacco etch virus protease was performed in
10mM Tris-HCl (pH 8.0), 0.5mM ethylenediaminetetraacetic
acid and 1mM dithiothreitol for 1 h at room temperature,
followed by incubation at 4 1C overnight. The cleaved Ab
peptides precipitated during the cleavage reactions and were
pelleted by centrifugation (4500 g, 20min, 4 1C), dissolved in
6M guanidinium chloride-HCl (pH 2.0) and purified via
reversed-phase high-performance liquid chromatography.
Peptides were eluted with CAN, aliquoted in Protein LoBind
Eppendorf tubes (Vaudaux-Eppendorf), lyophilized and stored
at  80 1C. The high purity and identity of the peptides were
verified by matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry using sinapinic acid as matrix.
Thioflavin T aggregation assays. Preparation of Ab
solutions and thioflavin T aggregation assays were per-
formed as described earlier.24,28 In brief, Ab variants were
dissolved in 10mM NaOH to concentrations of 100–150 mM.
Ab concentrations were determined via the absorbance of Ab
at 280 nm in 10mM NaOH (extinction coefficient at 280 nm
and pH 12 corresponding to a single tyrosine residue:
1730 M 1 cm 1). Stock solutions were kept on ice and were
used for aggregation experiments within 6 h. Aggregation
reactions were performed at 37 1C with 2.5 or 5mM Ab (final
concentration) in 10mM H3PO4-NaOH (pH 7.4), 100mM NaCl
and 35 mM thioflavin T in a volume of 1000 ml in stirred quartz
fluorescence cuvettes (1–0.4 cm). The thioflavin T concen-
tration was determined via its extinction coefficient of
36 000 M 1 cm 1 at 412 nm. Aggregation reactions were
started by a dilution of the Ab stock solution in 10mM NaOH
(prepared and ultracentrifuged immediately before use) with
an aggregation buffer mix, resulting in pH 7.4, and the final
concentrations indicated above. Thioflavin T fluorescence
emission at 482 nm (excitation at 440 nm; excitation and
emission slit at 1.6 nm) was monitored on a Quantamaster
(QM-7/2003) fluorescence spectrometer (Photon Technol-
ogy International, Birmingham, NJ, USA).
Cognitive–behavioral testing. A battery of well-validated
and carefully controlled tests was used to behaviorally
assess mice for motoric and cognitive performance.29 At
the time of testing, mice were weighed and examined for
general health measures to ensure that the mice were
physically able to conduct the cognitive–behavioral test.29
Locomotor activity in the open field test. According to
published procedures, mice were placed in the center of a
brightly-lit white Plexiglas box (50 50 cm2), and their
movements (distance traveled and average speed) were
tracked using ANY-maze video tracking software (Stoelting,
Wood Dale, IL, USA) for 5min.
Y-maze. Spatial working memory was assessed in mice
using the Y-maze (Y-shaped plastic maze, with 40 20 10
cm3 arm sizes). During a 5-min trial, the sequence of arm
entries was recorded using the ANY-maze Video Tracking
System (Stoelting). The percentage alternation was calcu-
lated as the ratio of actual to possible alternations (defined as
the total number of arm entries 2) 100%.
Barnes maze. The Barnes maze was used to assess
hippocampus-dependent spatial learning and memory.30
The Barnes maze consists of a gray, acrylic, circular disk
91 cm in diameter with 20 equally spaced holes (5 cm in
diameter) located 1.5 cm from the edge, and elevated 90 cm
above the floor. The platform was illuminated by a 100W
electric bulb located 110 cm above the center of the maze
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(150 lx), thus providing motivation for the animals to avoid the
open surface and escape into a small dark recessed
chamber (escape box) located under the platform. The
inclusion of false boxes that look the same as the target
escape box, but are too small to be entered, were used to
remove visual cues that might allow the mouse to discrimi-
nate the location of the escape hole from the other holes. A
cylindrical plastic start chamber (10.5 cm diameter, 9.5 cm
height) was used to hold mice in the middle of the maze at
the start of each trial. A web camera (Logitech, Zurich,
Switzerland) was placed 1.2m above the center of the maze
to record trials using the ANY-maze Video Tracking System
(Stoelting). Distinct spatial cues placed in a constant location
around the maze served as a reference point to learn the
position of the escape hole.
Mice completed 4 days of acquisition training with four trials
per day with an inter-trial interval of 10–15min. For each trial,
mice were placed in the start chamber in the middle of the
maze, and after 10 s, the start chamber was raised to start the
trial and themouse was allowed to explore the maze for 3min.
During these 3min, the latency to enter the escape box,
distance traveled, speed, time spent immobile and search
strategy used was measured, among other parameters. The
trial ended when the mouse successfully entered the escape
box or after the 3min had elapsed. If a mouse did not
successfully enter the escape box during the 3min, it was
placed back at the start position and gently guided to the
escape hole, where themouse remained in the escape box for
1min. At the end of each trial, mice were returned to their
holding cage until the next trial. To reduce intramaze odor
cues, the maze surface and escape box were cleaned with
70% ethanol after each trial. Search strategies were deter-
mined by examining individual track plots for each mouse per
day and classifying their ability to find the escape location as
either: (1) random search strategy—search patterns that
cross through the center of the maze in a completely random
manner; (2) serial search strategy—in which mice search
every hole or every other hole in a clockwise or counter-
clockwise systematic manner; or (3) spatial search strategy—
in which the mice were able to locate the escape box directly
plus or minus two adjacent holes within the target quadrant
only.
Statistical analysis. Data analysis was performed using the
Statistica 10.0 (StatSoft Inc, Tulsa, OK, USA) and SPSS 19.0
(16M, Schweiz, Zurich, Switzerland) statistical software. Tests
for normal distribution were performed before statistical
testing, according to the results of the Shapiro–Wilk and the
Kolmogorov–Smirnov test for normality, either Student’s t-test
or Mann–Whitney U-test for two sample groups or analysis
of variance was performed (followed by post-hoc Fischer’s
least significant difference analysis). A P-value o0.05 was
considered statistically significant. Error bars are s.e.m.
Results
Transgene expression and APP processing. The newly
generated E22DAb mice overexpress the human APP695
isoform containing the Swedish (K670NþM671L) and
Osaka (E693D) mutations. The Swedish double mutation
was introduced to increase the amount of total secreted Ab
without affecting the Ab42/Ab40 ratio. Several transgenic
founder lines were analyzed for brain expression of the full-
length human APP transgene, and a line expressing
transgene levels comparable to our APP transgenic arcAb
mouse model (expressing APP with the Swedish and Arctic
(E693G) mutations) and the widely established Tg2576 AD
mouse model (expressing APP with the Swedish mutation
alone) was chosen for further analysis (Figure 1a). Western
blot analysis of SDS extracts revealed similar full-length APP
and b-stub (C99) levels in the E22DAb, arcAb and Tg2576
mice (Figure 1a). a-Stub (C83) levels, however, were
significantly reduced in both E22DAb and arcAb mice as
compared with Tg2576 mice (Figure 1a). MSD assay
analysis of soluble APP levels from SDS brain extracts
revealed a two- to threefold reduction in sAPPa levels in the
E22DAb and arcAb mice. In contrast, sAPPb levels were
comparable to the Tg2576 mice (Figure 1b). These findings
indicate that both intra-Ab APP mutations at position 22 of
the Ab sequence specifically interfere with the a-secretase
processing of APP in vivo.
Age-dependent changes in Ab levels. As a next step, we
used MSD technology to determine Ab levels in four
sequentially extracted protein fractions from the cortical brain
tissue (Figure 2). In agreement with previous findings,27,31,32
Tg2576 and arcAb mice showed an age-dependent expo-
nential accumulation of Ab in detergent-insoluble (FA-
soluble) protein fractions (Figure 2e–k) that accompanied
the occurrence of parenchymal amyloid deposits in these
mouse models (data not shown). Ab accumulation occurred
earlier and was more pronounced in the arcAb mice as
compared with age-matched Tg2576 mice (Figure 2e–k), as
previously reported in immunohistological findings.27,31 In
contrast, most of the Ab in the E22DAb mice accumulated in
the detergent-soluble (SDS) protein fraction up to the age of
15 months (Figure 2a-c). MSD analysis of Tris buffer and
mild detergent (Triton X-100) extracts in the E22DAb mice
revealed only very low Ab levels as compared with the
Tg2576 mice (Figure 2a–c). In addition, E22DAb mice
(similar to the arcAb mice) showed four- to fivefold lower
plasma Ab levels than the Tg2576 mice (Supplementary
Figure 1). These results indicate that the lack of accumula-
tion of detergent-insoluble Ab in the E22DAb mice up to the
age of 15 months was not accompanied by a relative
increase in soluble brain or peripheral (plasma) Ab levels.
Western blot analysis of the four protein fractions at 15
months further confirmed the MSD findings (Supplementary
Figure 2). At 24 months of age, however, a significant
increase in detergent-insoluble (FA-soluble) Ab was
observed in the E22DAb mice (Figure 2d). This change in
Ab solubility provided the first biochemical evidence for a
substantial accumulation of fibrillar amyloid deposits in aged
E22DAb mice, even though FA-soluble Ab levels remained
relatively low in comparison to amyloid depositing Tg2576
and arcAb mice at 15 months (Figure 2b and c).
Late CAA in the absence of amyloid plaque deposition.
Immunostainings of paraffin-embedded brain sections from
aged E22DAb mice with Ab-specific antibodies showed no
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evidence of extracellular parenchymal amyloid deposition
up to an age of 15 months (Figure 3a and b). At 24 months
of age, however, extracellular vascular amyloid deposits
were observed in cortical and—more pronounced—
cerebellar leptomeningeal vessels (Figure 4a and b).
Vascular amyloid deposits were thioflavin S (Figure 4c)
and Congo red positive (Figure 4d), and were immunos-
tained with several Ab-specific antibodies (Figure 4a–f).
Immunostainings with Ab40- and Ab42-specific monoclonal
antibodies revealed that Ab40 was the dominant Ab species
deposited in the vessel walls of the E22DAb mice (Figure 4e
and f).
Early accumulation of intracellular Ab oligomers.
Although extracellular (vascular) amyloid deposits were
detectable in the E22DAb mice only as late as at the age
of 24 months, immunostaining of paraffin-embedded brain
sections with the monoclonal antibody 6E10 revealed
prominent intraneuronal accumulation of dot-like aggregates
mainly in hippocampal CA1 (Supplementary Figure 3a) and
cortical (Supplementary Figure 3b) neurons that were
observed already at the age of 3 months (data not shown).
Double immunostaining with a polyclonal antibody directed
against the APP C terminus (Supplementary Figure 3c and d)
showed little colocalization of 6E10 and APP immuno-
reactivity in the cortex and hippocampus (Supplementary
Figure 3e and f), thus excluding 6E10-positive aggregates as
full-length APP or APP C-terminal fragments. Immuno-
staining with Ab-specific antibodies directed against the
C terminus of Ab40 and Ab42 confirmed that the intra-
neuronal deposits indeed corresponded to Ab aggregates
(Supplementary Figure 4a–f). Interestingly, immunostaining
with the Ab40-specific antibody led to a more diffuse staining
of both dot-like aggregates and neuronal cell bodies and
Figure 1 Intra-amyloid b (Ab) mutations decrease a-cleavage in vivo. Transgene expression and Ab peptide precursor (APP) processing were compared in three mouse
models of Alzhemier’s disease (AD). (a) Western blot analysis of cortical SDS extracts from 3-month-old E22DAb mice in comparison with age-matched Tg2576 and arcAb
mice. Full-length APP and APP C-terminal fragments (C99 and C83) were detected with a C-terminal-specific APP antibody and values normalized to b-actin. Quantification
reveals significant reductions in a-stub (C83) levels in both transgenic mouse lines bearing the intra-Ab mutation. This results in an increased C99/C83 ratio in the E22DAb
and arcAb mice as compared with the Tg2576 mice. *Po0.05 E22DAb and arcAb vs Tg2576 (Mann–Whitney U-test). n¼ 4 per group. (b) MSD analysis of sAPPa and
sAPPb levels in cortical samples extracted with Tris buffer containing 2% SDS. In accordance with the results of the APP CTF analysis, sAPPb levels were not significantly
different among the three APP transgenic mouse lines, whereas sAPPa was reduced almost threefold in the E22DAb and arcAb mice as compared with the Tg2576 mice.
*P¼ 0.001 E22DAb and arcAb vs Tg2576 (Mann–Whitney U-test). n¼ 6–8 per group.
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processes (Supplementary Figure 4a, b and e), whereas the
Ab42-specific specifically stained compact intraneuronal
aggregates (Supplementary Figure 4c, d and f).
Further characterization of the intraneuronal Ab aggregates
in the E22DAbmice with several oligomer-specific (conforma-
tion-dependent) antibodies revealed that the dot-like Ab
Figure 2 Accumulation of detergent-insoluble amyloid b (Ab) at different ages in the three Alzhemier’s disease (AD) mouse models. MesoScale Discovery (MSD) analysis
of Ab38 (black column), Ab40 (gray column) and Ab42 (white column) in serially extracted cortical samples (Tris buffer, Tris buffer containing 1% Triton, Tris buffer containing
2% sodium dodecyl sulfate (SDS) and formic acid (FA)). (a) In E22DAb mice most of the Ab can be detected in the SDS-soluble protein fraction up to the age of 15 months,
whereas Tris buffer-soluble, Triton-soluble and FA-soluble Ab levels are comparatively low. Only at 24 months of age is detergent-insoluble Ab detected. (b) In contrast,
Tg2576 mice show higher soluble Ab levels in Tris and Triton fractions and a prominent age-dependent Ab accumulation in the detergent-insoluble FA fraction at 15 months.
(c) The 3-month-old arcAb mice show intermediate Tris- and Triton-soluble Ab levels (as compared with age-matched E22DAb and Tg2576 mice) and accumulation of Ab in
the FA fraction already at the age of 6 months. n¼ 6–9 per group.
Figure 3 Lack of amyloid deposition in 15-month-old E22DAb mice. (a–d) Immunostaining with antibody 6E10 reveals a complete absence of extracellular amyloid
deposits in 15-month-old E22DAb mice (a: cortex; b: hippocampus). In contrast, arcAb mice show a massive extracellular amyloid deposition at that age (c: cortex; d:
hippocampus). Scale bars: 250 mm (a–d). Ab, amyloid b.
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deposits were strongly stained by the polyclonal OC antibody
directed against fibrillar Ab oligomers33 (Figure 5a–d), but not
the A11 antibody directed against prefibrillar oligomers34
(Supplementary Figure 4g and h). OC-immunoreactive
intraneuronal deposits were observed in CA1 hippocampal
and cortical neurons as early as 3 months of age and
appeared to grow and become more compact as the mice
aged (Figure 5a–d). Strikingly, the intraneuronal oligomeric
Ab deposits were also recognized by 11A1 (Figure 5e and f),
a novel conformation-dependent monoclonal antibody speci-
fically designed against the turn between positions 22 and 23
of the Ab sequence. 11A1 has recently been shown to stain
intraneuronal Ab aggregates in brains of AD patients but not
APP transgenic mice.26
Early cognitive deficits in transgenic E22DAb mice.
Based on our previous findings in the arcAb mouse model
in which intracellular Ab deposits occurred concomitantly
with robust cognitive deficits, we hypothesized that the early
accumulation of intraneuronal oligomeric Ab deposits,
particularly in hippocampal brain regions of the E22DAb
mice, would also be accompanied by significant impairments
on several cognitive tasks. Both E22DAb mice and wild-type
littermates displayed, across all age groups, similar general
health measures, auditory–visual sensory integrity, compar-
able grip strength, intact righting and extension reflexes.
Assessment of body weight demonstrated equivalent body
weights across all experimental groups, for both males and
females. Locomotor and anxiety examination using the open
field test demonstrated the published phenotype of increased
locomotor activity and exploratory behavior, including
increased total distance traveled, less time immobile and
more time spent in the center zone, in transgenic mice (data
not shown). Cognitive assessment in the Y-maze demon-
strated a significant decrease in the percentage spatial
alternation rate for E22DAb mice at 3 months of age
(t(55)¼  3.16, Po0.005), 6 months of age (t(28)¼  1.727,
Po0.05) and 9 months of age (t(16)¼  1.772, Po0.05), as
compared with their wild-type littermates (Figure 6a). The
Barnes maze was also used at 3 months of age as a second
Figure 4 Aged E22DAb mice develop congophilic amyloid angiopathy (CAA) at 24 months. (aþ b) Immunostaining of amyloid-laden leptomeningeal vessels with
polyclonal anti-amyloid antibody directed against human pan-Ab in the cortex (a) and cerebellum (b) of a 24-month-old E22DAbmouse. (cþ d) Vascular amyloid deposits are
thioflavin S (c) and Congo red positive (d). Note the classical apple-green birefringence of Congo red-stained vessels under polarized light (d). (eþ f) Immunostainings with
Ab40-specific monoclonal antibody BA27 (e) and Ab42-specific monoclonal antibody BC05 (f) reveal that Ab40 is the dominant Ab species deposited in the vessel walls.
Scale bars: 125 mm (aþ b) and 40mm (c–f). Ab, amyloid b.
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hippocampus-dependent cognitive task to assess spatial
learning and memory. Results demonstrated that both wild-
type and transgenic E22DAb mice showed successful learn-
ing, with significantly lower latencies to escape over the 4
days of training (all P’so0.05; Figure 6b). Between geno-
types, a significant main effect was shown for E22DAb mice
(F(1,340)¼ 16.656, Po0.001). Fischer’s least significant dif-
ference post hoc analysis demonstrated a significantly longer
latency to escape for E22DAb mice, as compared with wild-
type littermates on day 3 (P¼ 0.01) and day 4 (P¼ 0.03), with
similar but nonsignificant trends on day 1 (P¼ 0.096) and day
2 (P¼ 0.095) (Figure 6b). Qualitative assessment of Barnes
maze search strategies revealed a decrease in spatial
search strategies in 3-month-old E22DAb mice (Figure 6d),
as compared with wild-type control mice (Figure 6c).
Unique aggregation properties of recombinant E22D-
mutated Ab peptides. In agreement with our previous
findings that both E22D Ab40 and E22D Ab42 readily formed
amyloid fibrils in vitro, we observed fibrillar (congophilic)
amyloid deposits in vivo in aged APP transgenic E22DAb
mice. Extracellular amyloid deposition in the E22DAb mice,
however, only occurred as leptomeningeal CAA at an
advanced age of 24 months (Figure 4), whereas wild-type
Ab-producing Tg2576 mice and E22G (Arctic) Ab-producing
arcAb mice accumulated fibrillar amyloid deposits at a much
earlier age (Figures 2 and 3).27,31 To further investigate the
biophysical basis of the E22D intra-Ab mutation leading to
early intracellular and very late extracellular amyloid deposi-
tion in vivo, we conducted in vitro thioflavin T aggregation
assays of recombinant E22D Ab40 and E22D Ab42 peptides.
E22DAb aggregation curves were compared with the
aggregation curves of Ab40 and Ab42 with wild-type or
Arctic sequence (Figure 7). Measurements were terminated
as the thioflavin T signal reached a plateau, after which the
different Ab preparations were further incubated for a total of
1 h, followed by western blot analysis. Results demonstrated
typical aggregation kinetics of wild-type Ab42 and E22G
Ab42 peptides involving a lag phase, an exponential growth
phase and a plateau phase of saturated fibril growth
Figure 5 Intraneuronal amyloid b (Ab) consists of fibrillar oligomers bearing a ‘toxic turn’ conformation. (a–d) Immunostaining with polyclonal OC antibody directed against
fibrillar Ab oligomers reveals age-dependent accumulation of intracellular oligomeric deposits in cortical (a and b) and CA1 hippocampal neurons (c and d). Note the temporal
change of intraneuronal oligomers from rather diffuse and smaller dot-like aggregates at 3 months of age (a and c) to bigger and more compact deposits at 15 months of age
(b and d). (e and f) Conformation-dependent monoclonal antibody 11A1 directed against the turn between positions 22 and 23 of the Ab sequence stains hippocampal (e) and
cortical (f) intraneuronal aggregates (representative immunostaining in a 15-month-old E22DAb mouse). Scale bar: 40mm (a–f).
Mice expressing the Osaka intra-Ab APP mutation
L Kulic et al
8
Translational Psychiatry
(Figure 7a and b). In contrast, no obvious lag phase and no
exponential growth phase were observed for E22D Ab42 at
2.5mM (Figure 7a) and—more obvious—at 5 mM initial
concentration (Figure 7b). Instead, E22D Ab42 showed a
constant non-exponential increase in thioflavin T fluores-
cence from time point 0 on and—in contrast to E22G and
wild-type Ab42—formed detergent-insoluble high-molecular-
weight aggregates immediately after reconstitution at pH 7.4,
as revealed by western blotting of the recombinant peptide
preparations that were used for the thioflavin T analysis
(Figure 7c). Thioflavin T analysis of recombinant Ab40
peptide variants revealed a dramatically accelerated fibril
formation for both E22D and E22G Ab40 in comparison to
wild-type Ab40 (Figure 7d). In contrast to E22D Ab42, E22D
Ab40 aggregation was characterized by a lag phase, an
exponential growth phase and a plateau phase with
unusually high absolute thioflavin T fluorescence values
indicating increased thioflavin T binding capacity of the E22D
Ab40 peptide as reported previously.24
In summary, thioflavin T analysis of recombinant E22D
Ab42 and E22D Ab40 aggregation kinetics confirmed our
previous findings of a highly increased fibrillogenic property of
single preparations of the two peptide variants.24
Inhibition of E22DAb aggregation in the presence of
wild-type Ab. The E693D APP mutation is one of the two
currently known familial AD mutations in the APP gene with a
recessive Mendelian trait of inheritance.9,35 The second
recessive mutation, A673V, has recently been shown to be
highly amyloidogenic in the homozygous state, but anti-
amyloidogenic in the heterozygous state as revealed by an
inhibition of Ab aggregation when mutated and wild-type
peptides were co-incubated.35 We hypothesized similar
effects on the aggregation kinetics when incubating mixtures
of the wild-type and E22D-mutated Ab peptides. Co-
aggregation of wild-type Ab42 with E22D Ab42 led to a
significant extension of the lag phase and a delay of the
growth phase in comparison to the aggregation of wild-type
Ab42 alone. This effect was specific for the E22D intra-Ab
mutation, as it was not observed with the E22G Ab42 variant.
In contrast, co-aggregation of E22G (Arctic) Ab42 with wild-
type Ab42 revealed a similar aggregation kinetics as E22G
Ab42 alone (see Figure 8a). Similarly, the aggregation of
E22D Ab40 peptides was also significantly delayed in
mixtures containing 50% wild-type Ab40, whereas co-
incubation of E22G Ab40 with wild-type Ab40 only slightly
delayed fibril formation in comparison to E22G Ab40 alone
(Figure 8b). In conclusion, only the E22D intra-Ab mutation
(but not the E22G variant) was associated with a significant
delay of aggregation in the heterozygous state, simulated by
equal mixtures with wild-type Ab peptides.
Inhibition of E22D Ab40 aggregation in the presence of
E22D Ab42. Based on our results that co-incubation of wild-
type Ab with E22DAb significantly delayed amyloid fibril
formation, we hypothesized that co-incubation of E22D
Ab40 with E22D Ab42 may have similar antifibrillogenic
effects. Therefore, recombinant E22D Ab40 and E22D Ab42
peptides were co-incubated in a physiological 9:1 ratio at
2.5 mM, and the increase in thioflavin T fluorescence was
monitored over time (Figure 8c). We found a dramatic delay
of the growth phase and a remarkable loss of absolute
Figure 6 Early cognitive deficits in E22DAb mice. (a) Cognitive assessment in the Y-maze demonstrates a significant decrease in the percentage spatial alternation rate
for E22DAbmice as compared with their wild-type (wt) littermates at 3, 6 and 9 months of age (Po0.05 for all comparisons; Student’s t-test). (b) Assessment of Barnes maze
spatial learning at the age of 3 months reveals that both wild-type and E22DAb transgenic mice show successful learning over the 4 days of training. However, E22DAbmice,
as compared with wild-type littermates, show significantly higher latencies to escape on day 3 (P¼ 0.01) and day 4 (P¼ 0.03), with similar but nonsignificant trends on day 1
(P¼ 0.096) and day 2 (P¼ 0.095) (analysis of variance (ANOVA), followed by post hoc Fisher’s least significant difference (LSD) analysis). (c and d) Qualitative assessment
of Barnes maze search strategies reveals a decrease in spatial and relative increase in serial search strategies in 3-month-old E22DAb mice (d) in comparison to wild-type
control mice (c). n¼ 22–24 per group. Ab, amyloid b.
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thioflavin T fluorescence when we compared the aggrega-
tion curve with the aggregation curve of E22D Ab40 alone
(Figures 7d and 8c). Again in contrast, 9:1 mixtures of E22G
Ab40 and E22G Ab42 resulted in rapid aggregation, similar
to E22G Ab40 alone (Figures 7c and 8c). These results
again reveal the strong aggregating properties of the E22G
mutation and the inhibitory effect of the E22D mutation
under conditions when different peptide species coexist, as
is the case in vivo.
Poor seeding of wild-type Ab42 aggregation by E22D
Ab42 fibrils. Based on the assumption that amyloid forma-
tion can be seeded by preformed amyloid fibrils, we finally
addressed the question whether preaggregated E22D Ab42
fibrils were capable of (a) seeding their own growth and (b)
seeding the growth of wild-type Ab42 fibrils. As control
experiments, wild-type Ab42 and E22G (Arctic) Ab42 fibrils
were incubated with preparations of their respective mono-
meric peptides, which resulted in an immediate increase in
Figure 7 Unique aggregation kinetics of recombinant E22DAb peptides in vitro. Fibril formation is measured via the absolute increase in thioflavin T fluorescence at
482 nm during aggregation. Aggregation of amyloid b (Ab) peptides (identical total monomer concentrations: 2.5mM in aþ c, 5 mM in b) at pH 7.4 and 37 1C is initiated by a 10-
fold dilution of Ab stock solutions in 10 mM NaOH with buffer. Average curves of three independent experiments are shown (±s.e.m.). (a and b) Thioflavin T analysis of E22G
(Arctic) Ab42 and wild-type (wt) Ab42 reveals that a typical aggregation kinetics with a lag phase, which is shorter for E22G Ab42 than wild-type Ab42, is followed by an
exponential growth phase that eventually reaches a plateau of saturated b-sheet formation. In contrast, no obvious lag phase and no exponential growth phase is observed for
E22D Ab42 at 2.5mM (a) and—more obvious—at 5 mM (b). Instead, E22D Ab42 is characterized by slow non-exponential fibril growth; however, it forms detergent-insoluble
high molecular weight (HMW) aggregates immediately after reconstitution at pH 7.4 as revealed by western blotting of the recombinant peptide preparations that were used for
the thioflavin T analysis at time point 0 and time point 60 of the assay (c). (d) In contrast to E22D Ab42, E22D Ab40—similar to E22G Ab40—shows an aggregation kinetics
characterized by a lag phase, an exponential growth phase and a plateau phase. Note the unusually high thioflavin T fluorescence values for E22D Ab40 in contrast to E22G
and wild-type Ab40, and the remarkably shorter lag phases of the E22-mutated Ab40 variants in comparison to the wild-type peptide. (e) In contrast to the amyloid b (Ab42)
analysis, western blot analysis of the Ab40 peptide variants reveals no immediate formation of detergent-insoluble HMW aggregates at time point 0 min. Only the E22G mutant
develops prominent HMW aggregates after 60 min.
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thioflavin T fluorescence without a lag phase, thus indicating
good seeding properties (Supplementary Figure 4a and b).
Incubation of preaggregated E22D Ab42 fibrils with fresh
preparations of E22D Ab42 peptide also resulted in an
immediate increase in thioflavin T fluorescence that was
steeper as compared with the aggregation curve of E22D
Ab42 in the absence of fibrillar seeds (Figure 7a and
Supplementary Figure 5c). However, when E22D Ab42 fibrils
were used for the seeding of wild-type Ab42, a significant
delay of fibril formation was observed, which indicated poor
seeding properties (Supplementary Figure 5e). In contrast,
E22G Ab42 fibrils appeared only slightly inferior to wild-
type Ab42 fibrils in seeding wild-type Ab42 aggregation
(Supplementary Figure 5d).
Discussion
Homozygous E693D APP mutation carriers develop an AD-
like clinical phenotype characterized by early memory
disturbances, visuospatial deficits and executive dysfunction,
followed by atypical neurological signs including cerebellar
ataxia and gait difficulties during later stages of the dis-
ease.9,36 Brain amyloid imaging by Pittsburgh Compound B
positron emission tomography revealed a very weak signal in
E693D APP mutation carriers with advanced dementia,
suggesting that AD-like clinical symptoms occurred in the
absence of relevant amyloid deposition in these patients.9,36
In vitro experiments with synthetic E22DAb40 andE22DAb42
peptide preparations demonstrated an enhanced oligomer-
ization propensity, but no fibril formation,9 and led to the
hypothesis that AD-like dementia in patients can be caused by
the sole presence of synaptotoxic Ab oligomers, which was
well in line with previous experimental findings.37–43 In
contrast to these initial in vitro findings, subsequent work,
including our own recent study with highly pure recombinant
peptide preparations, demonstrated that both E22D Ab40 and
E22DAb42 readily formed amyloid fibrils in vitro.20,24,44 Based
on these in vitro findings, we hypothesized that E22D Ab40
and E22D Ab42 would, at least in principle, also form amyloid
fibrils in vivo. Indeed, aged E22DAb mice accumulated
detergent-insoluble Ab and showed thioflavin S and Congo
red-positive amyloid deposits in leptomeningeal cortical
and—more pronounced—cerebellar vessels; in contrast to
the recently published E693Dmousemodel, which completely
lacked extracellular amyloid deposition even at an age of 24
months,22 E22DAb mice overexpress human APP at levels
comparable to those in the Tg2576 mouse line, and the
introduction of the Swedish double mutation results in an
additional increase in total Ab levels.6 Taken together, this
might explain the differences between our model and the
E693Dmice. Interestingly, CAA deposits in the E22DAbmice
were more pronounced in the leptomeningeal vasculature of
the cerebellum than in cortical vessels, which is in agreement
with recent amyloid positron emission tomography findings in
E693D mutation carriers showing a relative increase in
Pittsburgh Compound B retention in cerebellar brain
regions.36 The identification of CAA as a key neuropatholo-
gical feature of aged E22DAb mice adds the Osaka E693D
mutation to the list of vasculotropic intra-Ab APP mutations
essentially comprising all of the currently known mutations at
or around position 22 of the Ab sequence (for a review see
Kumar-Singh18). Our immunohistological analysis of CAA
deposits identified Ab40 as the major E22DAb species
depositing in the vessel walls of the E22DAb mice, which is
in line with previous findings in sporadic and familial AD
cases,45,46 including the Dutch E693Q APP mutation.47
Further experiments are needed to elucidate the mechanisms
underlying the vasculotropism of E22D-mutated Ab and
whether similar mechanisms as previously reported for the
Dutch mutation (that is, a reduced receptor-mediated clear-
ance across the blood–brain barrier) have a role.48,49
Figure 8 Anti-amyloidogenic property of E22DAb peptides in mixtures of
different Ab peptide variants. (a and b) Co-aggregation of E22D Ab42 with wild-
type (wt) Ab42 (a) or E22D Ab40 with wild-type Ab40 (b) leads to a significant
extension of the lag phase and a delay of the growth phase in comparison with the
aggregation of the respective Ab peptide variants alone (see Figure 7) (total
monomer concentrations for each peptide variant: 2.5mM). In contrast, co-
aggregation of 2.5mM E22G (Arctic) Ab42 with 2.5mM wild-type Ab42 (a) results in a
similar aggregation curve as with 2.5 or 5 mM E22G Ab42 alone (see Figure 7). Co-
aggregation of E22G Ab40 with wild-type Ab40 (b) only slightly delays b-sheet
formation in comparison with E22G Ab40 alone. (c) Co-aggregation of E22D Ab40
with E22D Ab42 in a physiological 9:1 ratio (total monomer end concentration in
solution: 2.5mM) leads to a strong inhibition of E22D Ab40 aggregation. Note the
dramatic delay of the growth phase and remarkable loss of absolute thioflavin T
fluorescence in comparison to E22D Ab40 alone (Figure 7). In contrast, 9:1
mixtures of E22G Ab40 and E22G Ab42 result in an aggregation curve very similar
to E22G Ab40 alone. Average curves of three independent experiments are shown
(±s.e.m.).
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E22DAb mice—similar to our previously reported arcAb
mice27—develop intraneuronal Ab aggregates that coincide
with cognitive deficits beginning at 3 months of age.
Intraneuronal Ab accumulation is generally believed to be
an early event in AD pathogenesis, although its relevance and
role in the disease process remain a controversial topic.50–52
This may be partly due to technical considerations, including
the use of nonspecific antibodies for the detection of
intraneuronal Ab. The intraneuronal Ab staining in our
E22DAb mouse model only partially colocalized with staining
of the APP C terminus, excluding false interpretation of Ab
staining emerging from full-length APP or APP C-terminal
fragments. Furthermore, intraneuronal Ab was stained by
different Ab C-terminus-specific antibodies, which do not
crossreact with APP or APP fragments, including BC05 and
BA27.53 These results therefore indicate that the intraneur-
onal aggregates in the E22DAbmice indeed correspond to Ab
and not accumulating APP/APP fragments. The assembly
state of the intraneuronal aggregates was characterized by
immunohistochemistry using several oligomer-specific anti-
bodies. Accumulation of intracellular oligomeric Ab species
has recently been reported in other APP transgenic mouse
lines, including the McGill-Thy1-APP mice,54 the 3Tg-AD55
and the E693D mice.22 Further immunohistological charac-
terization of the intraneuronal deposits in the E22DAb mice
revealed that the intraneuronal aggregates were strongly
stained by OC antibody, directed against fibrillar oligomers,
but not A11 antibody, which recognizes prefibrillar oligo-
mers.33,34 Interestingly, soluble fibrillar oligomers detected by
OCantibody (but not prefibrillar oligomers) have recently been
shown to be elevated in multiple brain regions of AD patients
and to correlate with cognitive dysfunction.56 Building on the
hypothesis that intra-Ab mutations at or around position 22 of
the Ab increase Ab fibrillogenesis through a facilitation of a
‘toxic turn’ conformation between positions 22 and 23 of the
Ab sequence,57 Murakami et al.26 developed a novel
monoclonal antibody (11A1) directed against this specific
conformational epitope of Ab42. In human AD brains, 11A1
stained both extracellular and intracellular Ab deposits,
whereas in APP transgenic Tg2576 mice, only extracellular
deposits were labeled.26 Interestingly, 11A1 stained intra-
neuronal Ab aggregates in the brains of the E22DAb mice,
suggesting that the oligomeric E22D-mutated Ab deposits
contained the ‘toxic turn’ conformation.
Western blot and MSD analysis of APP cleavage products
from cortical brain extracts revealed a relative increase in
amyloidogenic (b-secretase-mediated) APP processing in the
two mouse models bearing the E22 intra-Ab APP mutations,
which is in accordance with previous in vitro findings.21,58,59
As both E22DAb and arcAb mice overexpress similar full-
length APP, sAPPb and C99 levels, but significantly reduced
sAPPa and C83 levels, as compared with the Tg2576 mice,
we concluded that the two intra-Ab mutations specifically
interfered with the a-secretase cleavage of APP in vivo.
Previous in vitro reports in the Arctic mutation revealed that
E693G APP was not a poor substrate to a-secretase, but
instead reduced APP levels at the cell surface making Arctic
APP less available for a-secretase cleavage, and increasing
Ab levels, especially at intracellular locations.58 Similar to the
Arctic APP mutation, E693D APP overexpression in cell
culture was also associated with reduced extracellular Ab
levels in vitro.21,58,59 Although these results may imply similar
effects of the two intra-Ab mutations on APP processing, we
currently cannot exclude E693D APP as an inferior substrate
to a-secretase-mediated cleavage, thus leading to the relative
increase in amyloidogenic APP processing, as shown
previously for other intra-Ab APP mutations, including the
Flemish E692G APP mutation.60
MSD analysis revealed a marked reduction of buffer- and
Triton buffer-soluble brain Ab, as well as peripheral plasmaAb
levels, in particular when E22DAb mice were compared with
age-matched Tg2576 mice-expressing wild-type Ab. This
indicated that the absence of extracellular amyloid deposition
up to an age of 15 months was not associated with a relative
increase in soluble brain or plasma Ab levels. Instead, most of
the Ab accumulated in the SDS-soluble protein fraction likely
corresponding to intraneuronal Ab pools. These results are in
agreement with recent in vitro results from cell culture
experiments showing increased intracellular Ab accumula-
tion, but markedly reduced secreted Ab levels in E693D APP-
transfected cell lines.9,21,23 The early accumulation of
intracellular fibrillar oligomeric Ab deposits in brains of the
E22DAb mice is in line with the unique aggregation profiles of
the recombinant E22D Ab40 and E22D Ab42 peptides
showing accelerated b-sheet formation in thioflavin T aggre-
gation assays as compared with the respective wild-type Ab
peptides20,24,44 (and this study). When aggregation curves of
E22D, E22G and wild-type Ab40 and Ab42 were compared,
E22D Ab42 showed the highest fibrillogenesis propensity as it
aggregated without a lag phase and formed SDS-resistant
amyloid fibrils immediately after reconstitution in solution at
pH 7.4. However, E22D Ab42 fibril growth after reconstitution
in solution occurred only in a slow, non-exponential manner in
contrast to the other peptides, including E22D Ab40, whose
aggregation was characterized by an exponential growth
phase following lag phase. This slow fibril growth and lack of
exponential growth in E22DAb42may be a crucial factor in the
prevention of extracellular amyloid deposition in the E22DAb
mice.
Apart from A673V, a recently described familial AD APP
mutation in an Italian pedigree, E693D, is the second currently
known recessive APP mutation that is pathogenic only in the
homozygous state.9,35 Similar to the A673Vmutation, which is
antiamyloidogenic in the heterozygous state,35 our co-
aggregation experiments with recombinant E22DAb peptide
variants also revealed an inhibition of Ab aggregation when
mutated and wild-type peptides were co-incubated. In
contrast, co-aggregation of E22G (Arctic) Ab peptides with
the respective wild-type Ab peptides resulted in aggregation
curves very similar to those of the E22G Ab peptides alone.
Moreover, E22D Ab42 fibrils, in contrast to wild-type Ab42 and
E22G Ab42 fibrils, only very inefficiently seeded wild-type
Ab42 fibrillogenesis. These results provide a possible
explanation why heterozygous carriers of the E693Dmutation
do not develop the disease, whereas heterozygous carriers of
the autosomal dominant Arctic mutation develop dementia.
Hence, we propose the following hypothetical model to
explain the phenotype of the Osaka E693Dmutation, in which
E22DAb aggregation occurs primarily in intracellular compart-
ments where peptide concentrations are high enough to allow
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for aggregate formation (Supplementary Figure 6). Outside
the cell, E22DAb peptide variants may interact with each
other—and possibly also other peptides—in a way that results
in an inhibition of aggregation and amyloid seed formation.
Moreover, the E22DAb42 peptide shows specific aggregation
properties (slow non-exponential growth, lack of exponential
growth phase) that likely further prevent parenchymal amyloid
plaque deposition (Supplementary Figure 6). However, late
vascular amyloid deposition occurs possibly due to the
vasculotropism of the E22-mutated Ab peptide variant and
age-related changes along perivascular clearing pathways
(Supplementary Figure 6).
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